CoreFill Plus Sub-Q Lidocaine (1x1.1ml)

CoreFill Plus Sub-Q acts as a mechanical support, physically displacing tissue to create sharp angles and restore lost volume. Its high-viscosity structure allows it to withstand the natural weight of facial tissues and gravity. Unlike skin boosters that focus on epidermal hydration, this filler provides the skeletal support necessary for full-face rejuvenation and profile balancing.

Not advised during breastfeeding—limited data on transfer via milk and infant safety; postpone elective procedures.

The formulation contains 24 mg/ml of monophasic cross-linked Sodium Hyaluronate and 0.3% Lidocaine hydrochloride. This concentration is optimized for structural stability and long-term volume retention.

Dosage is individualized based on the patient's anatomical deficiency and desired level of projection. For structural jawline or cheek work, 1.0 ml per side is standard. Practitioners should evaluate if 0.5 ml of filler is sufficient for minor nasal bridge refinements before utilizing the full syringe capacity. Deep placement is required to ensure the gel integrates properly without visible migration, similar to the protocols used for Regenovue Deep Plus Lidocaine.

Common reactions include temporary redness, deep tissue tenderness, and localized purple bruising at the injection sites. These effects typically resolve within 7 to 14 days. To uphold medical safety standards, practitioners must always have Liporase (Hyaluronidase) available in the clinic to manage any unexpected aesthetic results or vascular concerns immediately.

Avoid alcohol for 24h before and 48h after the procedure. Alcohol is a vasodilator that can increase blood flow to deep injection points, potentially worsening post-injection swelling and increasing the risk of significant hematomas in the treated area.

Treatment is strictly contraindicated. No clinical safety data exists for the use of high-density cross-linked HA fillers during pregnancy or breastfeeding. Practitioners must remain vigilant for signs of vascular occlusion in all patients and defer elective procedures for pregnant individuals to ensure the highest safety standards.